The ALDH2 rs671 variant increases platelet activation and arterial thrombosis by causing aldehyde and ROS buildup, suggesting ALDH2 as a new antiplatelet target.
Does the Aldh2 rs671 variant enhance platelet activation and arterial thrombosis?
The ALDH2 rs671 variant enhances platelet activation and arterial thrombosis, identifying ALDH2 as a potential novel antiplatelet target for patients at risk of myocardial infarction.
Absolute Event Rate: 0% vs 0%
The Aldh2 rs671 variant, which impairs ALDH2 function, increases platelet activation and thrombus formation in vivo through aldehyde accumulation and reactive oxygen species buildup. Abnormal ACAD10 homeostasis might also contribute to this hyperactivity by enhancing platelet mitophagy. Our findings suggest potential of ALDH2 as a novel antiplatelet target. Future studies are needed to explore the effects of more aggressive antiplatelet therapy for patients at risk of myocardial infarction who carry the Aldh2 rs671 mutation.
Sun et al. (Fri,) reported a other. The ALDH2 rs671 variant increases platelet activation and arterial thrombosis by causing aldehyde and ROS buildup, suggesting ALDH2 as a new antiplatelet target.